Magnolia Medical Technologies said yesterday that it filed another legal action against blood-culture-focused device developer Kurin, this time claiming the company has infringed on patents related to its Steripath technology.
The Seattle-based company asserts that Kurin is infringing upon four patents related to its Steripath blood collection technology with its Kurin Lock product.
Magnolia Medical said that the “four patents represent and cover years of Magnolia’s research and development,” and added that it plans to “vigorously defend its technology.” The company said that it is seeking damages and a permanent injunction barring the production, use and selling of the Kurin Lock device.
“Magnolia uses its technology to decrease patient risk by reducing misdiagnosis and mistreatment of sepsis, which also strongly supports antibiotic stewardship. Dr. Richard Patton and I have spent more than a decade developing unique medical innovations that deliver scientifically proven results, and we are committed to making sure Steripath and its future are appropriately protected, ensuring that patients and hospitals will benefit from Magnolia’s technology,” CEO Greg Bullington said in a press release.
Last August, Magnolia said it filed a suit agianst Kurin claiming the company “mischaracterized its clinical data as well as the functionality and ease of use of its device.”